Seeking Alpha

After struggling to make recommendations about the product, an FDA panel rejects Hemispherx...

After struggling to make recommendations about the product, an FDA panel rejects Hemispherx Biopharma's (HEB) chronic fatigue syndrome treatment Ampligen, saying it isn't ready for marketing. Several panel members struggled with their decisions because it appears the drug works in certain patients even if it wasn't strongly shown in the clinical data presented to the panel. Shares -20% AH.
Comments (7)
  • medic11
    , contributor
    Comments (25) | Send Message
     
    So there it is, down 20% AH. Now how to play it? Just sell it and take the loss? What else do they have lined up anyway?
    20 Dec 2012, 07:51 PM Reply Like
  • coastside1000
    , contributor
    Comments (125) | Send Message
     
    morons
    20 Dec 2012, 08:11 PM Reply Like
  • cybericius
    , contributor
    Comments (8) | Send Message
     
    I would keep it if you don't need the money urgently...
    20 Dec 2012, 10:34 PM Reply Like
  • 411Hound
    , contributor
    Comment (1) | Send Message
     
    The FDA should be ashamed. Clearly the drug helps some people significantly. There is absolutely nothing on the market for CFS except 'snake oil' remedies. A great injustice has been done. How many more people must rot away, die or commit suicide before the FDA gives its approval?
    21 Dec 2012, 12:18 AM Reply Like
  • RalphTed
    , contributor
    Comment (1) | Send Message
     
    I am sure if they had a lot of money to give the FDA it would have been fast tracked like many of the drugs FDA approves and later ecalls. Get a new review panel who is impartial and not looking for the money to fund the FDA.
    21 Dec 2012, 12:44 AM Reply Like
  • robinandthe7hoods
    , contributor
    Comments (2) | Send Message
     
    This meeting was an absolute travesty.The FDA will reject this also,as most of the FDA panel will be from many different backgrounds and will not know enough about the disease to look closer at the information at hand.This panel today may have set CFS research back 30 years.What gives anyone a reason to spend millions on CFS when they could be beating their heads against the wall.This panel would have better served CFS by voting to pass Ampligen,on condition of another lengthy trial.But,no they just dismissed it as a joke,more or less.Where do all of these sufferers go?
    21 Dec 2012, 01:26 AM Reply Like
  • vmsh72
    , contributor
    Comments (2) | Send Message
     
    it will go up, surely
    21 Dec 2012, 02:10 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs